Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Major shareholder announcement
Company announcement no. 21 – 2324 May 2023 Major shareholder announcement Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that NTG Nordic Transport Group A/S (“NTG”) owns a total of 1,135,838 treasury shares of nominally DKK 20 (in total nominally DKK 22,716,760), hereby exceeding 5% of the total share capital of NTG.The increase in treasury shares is a result of NTG's ongoing share buy-back program.Additional information For additional...
Nasdaq GlobeNewswire
24/05/2023
Comparator Drug Sourcing Market to Expand at 3.5% CAGR from 2023 to 2031|Growth…
In January 2023, Avantor, Inc (NYSE: AVTR) one of the leading companies in the market announced a multi-year supply and services agreement with Catalent, Inc. (NYSE: CTLT). Catalent is a major global firm that works on developing and supplying solutions that enable providing patients with better treatments worldwide. As per the agreement, Avantor is to be the primary provider of various laboratory supplies, production and clinical materials, and services to Catalent. In January 2023 ,...
PR Newswire
24/05/2023
Alvotech and Advanz Pharma extend strategic partnership to commercialize five…
Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in EuropeThe agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and three additional early-stage undisclosed biosimilar candidatesAdvanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialization, and patient accessAlvotech (NASDAQ: ALVO), a global biotech company...
Nasdaq GlobeNewswire
24/05/2023
BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate…
BRY812 is a LIV-1 targeting ADC developed on BioRay's CysLink™ technology platform where highly stable conjugation is created through irreversible chemistry. By binding to LIV-1 on the surface of tumor cells, the ADC-target complex enters the tumor cell's lysosome through endocytosis, releasing small molecule toxins that selectively kill tumor cells. In pre-clinical pharmacological studies, BRY812 demonstrated significant antitumor activity in various tumor models. Compared to other ADCs…
PR Newswire
24/05/2023
Disclosure of voting rights for Chairman of the Board
Oslo, 24 May 2023. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 25 May 2023. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 5,590,554 additional shares. In total, Mr. Bøhn will…
Nasdaq GlobeNewswire
24/05/2023
InProTher Announces EUR 6M Seed Financing with the Participation of the European…
InProTher has generated robust pre-clinical, proof-of-concept data that demonstrates therapeutic potential for multiple oncology indications including pancreatic, ovarian, breast and prostate cancer. It plans to enter First-In-Human (FIH) trials in 2024. InProTher has generated robust pre-clinical, proof-of-concept data that demonstrates therapeutic potential for multiple oncology indications including pancreatic, ovarian, breast and prostate cancer. It plans to enter First-In-Human (FIH)...
PR Newswire
24/05/2023
Iraqi Patient Successfully Undergoes Robotic-Assisted CABG Surgery at Manipal…
Unlike traditional CABG surgery, robotic-assisted CABG enables patients to experience a faster recovery time, minimal scarring, and potentially improved graft placement, thanks to its minimally invasive technique. The procedure also incorporates continuous one-lung ventilation (OLV), an advanced technique that significantly lowers the risk of complications during surgery, including bleeding, infection, and lung collapse. Unlike traditional CABG surgery, robotic-assisted CABG enables patients…
PR Newswire
24/05/2023
XNK Therapeutics to present at ABG Sundal Collier's Life Science Summit in…
For more information, please contact: For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail:johan.liwing@xnktherapeutics.com About XNK Therapeutics AB XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company is at the forefront of the development of autologous NK cell-based products using its proprietary...
PR Newswire
24/05/2023
Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive…
Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive OfficerZug, Switzerland& Egham, UK – 24 May 2023– Essential Pharma, an international specialty pharma company focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, today announces the appointment of Emma Johnson as Chief Executive Officer. Steen Vangsgaard is stepping down from the business...
Nasdaq GlobeNewswire
24/05/2023
BioSenic and Pluristyx sign term sheet for market availability of ALLOB…
INSIDE INFORMATION Potential license agreement to produce and commercialize original and transformed ALLOB cellsBioSenic to potentially receive royalty rates on net salesup to 25% Mont-Saint-Guibert, Belgium ,May 24 th 2023 , 7 .00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, today announces the signing of a term sheet...
Nasdaq GlobeNewswire
24/05/2023
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to…
"The opioid crisis continues to weigh heavily on US society with approximately 80,000 opioid overdose deaths annually.5 Brixadi offers US patients and healthcare professionals a new and effective treatment option for opioid use disorder, with both weekly and monthly dosing to meet patient's individual treatment needs," says Dr. Fredrik Tiberg, President & CEO of Camurus. "Based on the success of Buvidal in Europe, Australia and other territories, we see a significant…
PR Newswire
24/05/2023
ESOC 2023: AI tool outperforms human emergency call handlers in identifying…
The results, evaluated on calls from 2021, revealed that the AI framework performed more effectively than emergency call handlers in identifying stroke cases. The AI framework achieved a recall (sensitivity) of 63.0% and a precision (positive predictive value) of 24.9%, which resulted in an F1 score of 35.7. In contrast, emergency call handlers had a recall of 52.7% and precision of 17.1%, resulting in an F1 score of 25.8. The results, evaluated on calls from 2021, revealed that the AI...
PR Newswire
24/05/2023
GENFIT Announces Publication of the Development and Validation of NIS2+™ in the…
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland);May 23 , 2023-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of the development and validation of NIS2+ ™in the Journal of Hepatology . 1 NIS2+™ is a next-generation technology for the diagnosis of at-risk Non-Alcoholic Steatohepatitis...
Nasdaq GlobeNewswire
23/05/2023
ERYTECH announces the availability of the exemption document relating to the…
PRESS RELEASEERYTECH announces the availability of the exemption document relating to the proposed combination with PherecydesLyon (France), May 23, 2023 - ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it has published the exemption document relating to the proposed combination with Pherecydes . The...
Nasdaq GlobeNewswire
23/05/2023
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor…
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and, if approved, has the potential to be the first selective oral TYK2 inhibitor in dermatomyositis Mechelen , Belgium; 23 May 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient was dosed in GALARISSO, the Phase 2 dermatomyositis...
Nasdaq GlobeNewswire
23/05/2023
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of…
Company announcement – No. 22 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, May 23, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 23,491 divided into 23,491 new shares with a nominal value of DKK 1 each...
Nasdaq GlobeNewswire
23/05/2023
MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference
NEWS RELEASE May23 , 2023, 4PM ET/ 22:00 CETMDxHealth to Present at the 43 rdAnnual William Blair Growth Stock ConferenceIRVINE, CA, and HERSTAL, BELGIUM– May 23, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage precision diagnostics company, today announced that Michael McGarrity, Chief Executive Officer, will present at William Blair's 43rd Annual Growth Stock Conference on Thursday, June 8, 2023, at 1:00pm ET...
Nasdaq GlobeNewswire
23/05/2023
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; May 23, 2023 –Genmab A/S (Nasdaq: GMAB) will increase its share capital by 33,098 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:5,408 shares at DKK 1,025.00, 547 shares at DKK 1,032.00, 125 shares at DKK 1,050.00, 515 shares at...
Nasdaq GlobeNewswire
23/05/2023
Cutting Tools Market to Hit $13.26 Bn by 2028, Launch of New Product with…
To Know More, Download the Free Sample Report:https://www.arizton.com/request-sample/3803 Browse In-Depth TOC on the Cutting Tools Market 128 – Tables 142 – Charts 338 – Pages Globally, new construction and remodeling in the residential sector are on the rise among customers. The COVID-19 pandemic has brought about a few emerging characteristics and disordering for the new-age construction and remodeling era across the expanding industry. Post-pandemic, people focus on...
PR Newswire
23/05/2023
Tangential Flow Filtration Market worth $3.6 billion | MarketsandMarkets
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72081607 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72081607 Browse in-depth TOC on "Tangential Flow Filtration Market" 410 - Tables 43 - Figures 359 - Pages Tangential Flow Filtration Market Scope: In 2022, the systems segment accounted for the largest share of the product segment in the Tangential Flow filtration market...
PR Newswire
23/05/2023
Curium Announces Last Patient Enrolled in Their Phase 1/2 SOLAR Clinical Trial…
/2 study evaluating the safety, biodistribution, and image quality of Copper Cu64 PSMA I&T injection to detect metastatic prostate cancer in PET imaging. Michael Patterson, CEO – North America at Curium commented,“We are pleased to complete the Phase 1/2 SOLAR study enrollment ahead of schedule. We are excited to use Curium's centralized Copper-64 production capabilities and our industry leading distribution network in upcoming Phase 3 trials. As we work globally to redefine the...
Nasdaq GlobeNewswire
23/05/2023
Heatless Hair Curler Market to Reach $259.3 Million, Globally, by 2032 at 4.8%…
Download Free Sample of Report: https://www.alliedmarketresearch.com/request-sample/75093 Download Free Sample of Report:https://www.alliedmarketresearch.com/request-sample/75093 Prime determinants of growth The heatless hair curler market is driven by factors such as rise in demand for non-damaging and non-invasive hair styling products, rise in the popularity of DIY hair styling, and the surge in understanding of the damaging effects of heat styling on hair. However, one of...
PR Newswire
23/05/2023
Report of transactions of shares and related securities of Bavarian Nordic by…
COPENHAGEN, Denmark, May 23, 2023– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associated a)NameJean-Christophe May 2.Reason for the notification a)Position/statusExecutive Vice...
Nasdaq GlobeNewswire
23/05/2023
Eurobio Scientific becomes one of the first European companies to obtain IVDR1…
Eurobio Scientific becomes one of the first European companies to obtain IVDR 1 CE marking of PCR tests Fundamental milestone successfully completedCompetitive advantage in a more restrictive regulatory environmentNew demonstration of Eurobio Scientific know-how Paris, May23 , 2023 –5h45 pmEurobio Scientific(FR0013240934, ALERS, PEA-PME eligible), a leading French group inin vitrospecialty medical diagnostics and life sciences, announces...
Nasdaq GlobeNewswire
23/05/2023
Altri Comunicati
